Literature DB >> 10771287

Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons.

R L Popp1, D M Lovinger.   

Abstract

The N-methyl-D-aspartate (NMDA) receptor has been implicated as a putative sight of action for acamprosate, a novel drug that reduces craving for alcohol. The purpose of this study was to assess the effect of acamprosate on the function of native NMDA receptors expressed in primary cultured striatal and cerebellar granule cells, as well as ethanol inhibition and spermine modulation of these receptors, using whole-cell patch-clamp electrophysiological techniques. Under all circumstances, acamprosate (0.1-300 microM) did not alter NMDA- or glutamate-induced currents. Acamprosate did not alter the inhibitory effects of ethanol (10-100 mM) on receptor function. In a subpopulation of striatal neurons, acamprosate did reverse the potentiating effects of spermine. These findings indicate that although acamprosate may modify polyamine modulation of the NMDA receptor, acamprosate alone does not alter receptor function nor does it modify ethanol inhibition of this receptor expressed in primary cultured striatal and cerebellar granule neurons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10771287     DOI: 10.1016/s0014-2999(00)00195-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  25 in total

Review 1.  Glutamatergic targets for new alcohol medications.

Authors:  Andrew Holmes; Rainer Spanagel; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2013-09-01       Impact factor: 4.530

Review 2.  Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.

Authors:  Philippe De Witte; John Littleton; Philippe Parot; George Koob
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Role of altered structure and function of NMDA receptors in development of alcohol dependence.

Authors:  József Nagy; Sándor Kolok; András Boros; Péter Dezso
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 4.  The development of acamprosate as a treatment against alcohol relapse.

Authors:  Peter R Kufahl; Lucas R Watterson; M Foster Olive
Journal:  Expert Opin Drug Discov       Date:  2014-09-26       Impact factor: 6.098

Review 5.  Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Authors:  Joseph T Coyle
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

6.  Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.

Authors:  M Scott Bowers; Billy T Chen; Jonathan K Chou; Megan P H Osborne; Justin T Gass; Ronald E See; Antonello Bonci; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2007-09-02       Impact factor: 4.530

7.  Pharmacoprophylaxis of alcohol dependence: Review and update Part I: Pharmacology.

Authors:  Sandeep Grover; Gaurav Bhateja; Debasish Basu
Journal:  Indian J Psychiatry       Date:  2007-01       Impact factor: 1.759

Review 8.  How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective.

Authors:  Peter Clapp; Sanjiv V Bhave; Paula L Hoffman
Journal:  Alcohol Res Health       Date:  2008

9.  The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration.

Authors:  Thorsten R Doeppner; Jens R Pehlke; Britta Kaltwasser; Jana Schlechter; Ertugrul Kilic; Mathias Bähr; Dirk M Hermann
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-29       Impact factor: 6.200

10.  Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice.

Authors:  Ben Lewis; Dennis J Morrell; Justin M Farook; Ali Krazem; John M Littleton; Susan Barron
Journal:  Physiol Behav       Date:  2008-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.